This company has been acquired
EQRx Future Growth
Future criteria checks 2/6
EQRx is forecast to grow revenue at 123.3% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 28.2% |
Revenue growth rate | 123.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 07 Oct 2023 |
Recent future growth updates
No updates
Recent updates
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely
Jul 25EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Feb 22We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate
Nov 08EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs
Aug 28 EQRx GAAP EPS of -$0.17 beats by $0.03
Aug 11Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation
Jul 24We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
Apr 08EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Dec 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 3 | N/A | N/A | N/A | 1 |
12/31/2024 | 1 | N/A | N/A | N/A | 1 |
12/31/2023 | N/A | N/A | N/A | N/A | 1 |
9/30/2023 | N/A | -260 | -332 | -330 | N/A |
6/30/2023 | N/A | -263 | -332 | -330 | N/A |
3/31/2023 | N/A | -272 | -320 | -319 | N/A |
12/31/2022 | N/A | -169 | -288 | -287 | N/A |
9/30/2022 | N/A | -146 | -262 | -262 | N/A |
6/30/2022 | N/A | -100 | -242 | -242 | N/A |
3/31/2022 | N/A | -53 | -214 | -214 | N/A |
12/31/2021 | N/A | -100 | -184 | -183 | N/A |
9/30/2021 | N/A | -279 | -276 | -275 | N/A |
6/30/2021 | N/A | -296 | -289 | -286 | N/A |
3/31/2021 | N/A | -269 | -260 | -257 | N/A |
12/31/2020 | N/A | -250 | -244 | -242 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EQRX's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if EQRX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if EQRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EQRX's revenue (123.3% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: EQRX's revenue (123.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EQRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/11/10 14:30 |
End of Day Share Price | 2023/11/08 00:00 |
Earnings | 2023/09/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EQRx, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Chris Shibutani | Goldman Sachs |
Akash Tewari | Jefferies LLC |
Christopher Schott | J.P. Morgan |